452 filings
Page 6 of 23
6-K
913n3kw
26 Jan 22
Current report (foreign)
4:30pm
6-K
4o3lph4zjo274e6a94ug
19 Jan 22
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies
4:30pm
F-6EF
xev9z3 vv
7 Jan 22
Automatic registration for ADRs (foreign)
4:08pm
424B5
pfemr 2s6z0z16
3 Jan 22
Prospectus supplement for primary offering
9:41pm
6-K
talt2cnyaklxx
3 Jan 22
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering
9:40pm
6-K
c6vt3wiq5dit585ind
21 Dec 21
Current report (foreign)
4:30pm
6-K
5bh7yulz3nxjwlfqy
3 Dec 21
Current report (foreign)
4:30pm
6-K
612zs66i r6nyq
1 Dec 21
Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders
5:16pm
6-K
af3mv6p15ki9s
25 Oct 21
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program
4:48pm
EFFECT
5mj3q 0czmw7cxepy
4 Oct 21
Notice of effectiveness
12:15am
EFFECT
3qn5 9w74xi
4 Oct 21
Notice of effectiveness
12:15am
EFFECT
tagykkz5sbudjka
4 Oct 21
Notice of effectiveness
12:15am
EFFECT
c95m 38tyie860b
4 Oct 21
Notice of effectiveness
12:15am
POS AM
6ihikyayo by1ecksud
30 Sep 21
Prospectus update (post-effective amendment)
5:05pm
POS AM
fkttzz im6mncjy014
30 Sep 21
Prospectus update (post-effective amendment)
5:04pm
POS AM
62uykinlix
30 Sep 21
Prospectus update (post-effective amendment)
5:03pm
POS AM
8s51r2
30 Sep 21
Prospectus update (post-effective amendment)
5:01pm
6-K
9x0fuj
22 Sep 21
Current report (foreign)
4:36pm
EFFECT
ho8nntai5y79iis7n xz
1 Sep 21
Notice of effectiveness
12:15am
CORRESP
8qoaa
30 Aug 21
Correspondence with SEC
12:00am